Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition
ConclusionsIn patients that responded to intracerebral immunotherapy in our institutional trial, HRQoL and NCF remained stable over time, suggesting that no detrimental effect on cognitive function or quality of life may be expected with this treatment approach. Furthermore, there seems to be an overall tendency for responders to score better on HRQoL and NCF than non-responders at baseline. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 19, 2024 Category: Cancer & Oncology Source Type: research
Comment on “Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control’’
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 18, 2024 Category: Cancer & Oncology Source Type: research
Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 18, 2024 Category: Cancer & Oncology Source Type: research
The detrimental effect of biopsy preceding resection in surgically accessible glioblastoma: results from the national cancer database
ConclusionsPre-operative biopsies for surgically accessible GBM are associated with worse survival despite subsequent resection compared to patients undergoing upfront resection. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 16, 2024 Category: Cancer & Oncology Source Type: research
Effects of cognitive-motor intervention for pediatric posterior fossa tumor survivors: results of a pilot study
AbstractThe purpose of this prospective pilot study was to evaluate the feasibility and effects of cognitive-motor intervention on the cognitive and motor abilities of pediatric survivors of posterior fossa tumors. The study involved patients aged 7 to 18 years with cognitive deficits who had completed primary treatment for posterior fossa tumors. 25 participants (Mage=11.3 ± 2.93, 64% male; 17 medulloblastoma, 1 ependymoma, 1 desmoplastic medulloblastoma, 6 piloid astrocytoma; 22 in remission (Mmonths =45), 3 in stabilization (Mmonths=49)) were recruited from the Research Institute for Brain Development and Peak Per...
Source: Journal of Neuro-Oncology - March 15, 2024 Category: Cancer & Oncology Source Type: research
Correction to: Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 15, 2024 Category: Cancer & Oncology Source Type: research
Correction to: Prognostic factors analysis of diffuse midline glioma
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 15, 2024 Category: Cancer & Oncology Source Type: research
About the incompleteness of our models
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 12, 2024 Category: Cancer & Oncology Source Type: research
Fractionated stereotactic radiotherapy in craniopharyngiomas: A systematic review and single arm meta-analysis
ConclusionDespite limitations and risks, FSRT shows promise as a viable therapeutic option for craniopharyngiomas, offering notable benefits for visual functions and tumor control. Further research is required to better understand the associated risks, benefits, and clinical utility. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 8, 2024 Category: Cancer & Oncology Source Type: research
The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study
ConclusionIn our series, adjuvant treatment after radiotherapy can be useful in improving OS of patients with H3K27-altered DMG. When feasible another systemic treatment after treatment progression could be proposed. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 8, 2024 Category: Cancer & Oncology Source Type: research
Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis
ConclusionIn nonanaplastic meningiomas, Lutathera ®’s antitumoral activity appeared delayed and more likely observed at six months, while no major response was observed under treatment. Moreover, its antitumoral activity persisted for 12–18 months following treatment initiation. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 7, 2024 Category: Cancer & Oncology Source Type: research
Inhibition of BMP signaling pathway induced senescence and calcification in anaplastic meningioma
ConclusionsThe GREM2-BMPR1A-tryptophan metabolic pathway in meningiomas is a potential new therapeutic target. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 6, 2024 Category: Cancer & Oncology Source Type: research
Correction to: Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 6, 2024 Category: Cancer & Oncology Source Type: research
Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1
ConclusionsImprovement in characterization of MEKi toxicities and their management is important to develop treatment guidelines for pediatric and young adult patients with NF1 on MEKi therapy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 5, 2024 Category: Cancer & Oncology Source Type: research
Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors
ConclusionsCSF-TC density may carry prognostic value in patients with LMD from solid tumors. Integrating CSF-TC density into LMD patient risk-stratification may help guide treatment decisions. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - March 5, 2024 Category: Cancer & Oncology Source Type: research
